Kiyang-yang, a West-African Postwar Idiom of Distress

In 1984, a healing cult for young barren women in southern Guinea Bissau developed into a movement, Kiyang-yang, that shook society to its foundations and had national repercussions. “Idiom of distress” is used here as a heuristic tool to understand how Kiyang-yang was able to link war and post-war-related traumatic stress and suffering on both individual and group levels. An individual experience born from a traumatic origin may be generalized into an idiom that diverse sectors of society could embrace for a range of related reasons. We argue that, for an idiom to be understood and appropriated by others, there has to be resonance at the level of symbolic language and shared experiences as well as at the level of the culturally mediated contingent emotions it communicates. We also argue that through its symbolic references to structural causes of suffering, an idiom of distress entails a danger for those in power. It can continue to exist only if its etiology is not exposed or the social suffering it articulates is not eliminated. We finally argue that idioms of distress are not to be understood as discrete diagnostic categories or as monodimensional expressions of “trauma” that can be addressed

Validation of the Brief Fear of Negative Evaluation Scale-II in patients with systemic sclerosis: A Scleroderma Patient-centered Intervention Network Cohort study

Item does not contain fulltextObjective: Fear of negative evaluation is a common concern among individuals with visible differences but has received limited attention in systemic sclerosis (SSc), which can involve substantial changes to appearance. The Brief Fear of Negative Evaluation Scale (BFNE) was specifically designed to evaluate fear of negative evaluation. There are currently three versions of the BFNE with strong demonstrated measurement properties: two eight-item versions (BFNE-S, BFNE-8) and one 12-item version (BFNE-II). The present study evaluated these versions in SSc, and identified the most appropriate version for use among SSc patients. Methods: Participants were 1010 patients with SSc enrolled in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. Multiple group confirmatory factor analysis, Cronbach's alpha, and Pearson product-moment correlations were used to evaluate structural validity, internal consistency reliability, and convergent and divergent validity, respectively. Results: Confirmatory factor analysis demonstrated that one-factor models fit acceptably well for the 12-item BFNE-II, the eight-item BFNE-S, and the eight-item BFNE-8. All Cronbach's alphas were excellent (BFNE-II: 0.98; BFNE-S: 0.97; BFNE-8: 0.96), and all versions had comparable associations with measures of social anxiety, body-related attitudes, depression, age, and education. Conclusion: Psychometric support was found for all three versions of the BFNE, though the longer 12-item BFNE-II did not improve measurement compared to the shorter eight-item versions. Of these two, the BFNE-S has been more widely studied with strong validity data in a greater number of populations. Therefore, the BFNE-S is recommended to assess fear of negative evaluation among patients with SSc.7 p

Examination of the association of sex and race/ethnicity with appearance concerns: A Scleroderma Patient-centered Intervention Network (SPIN) cohort study

OBJECTIVES: Appearance concerns are common in systemic sclerosis (SSc) and have been linked to younger age and more severe disease. No study has examined their association with sex or race/ethnicity. METHODS: SSc patients were sampled from the Scleroderma Patient-centered Intervention Network Cohort. Presence of appearance concerns was assessed with a single item, and medical and sociodemographic information were collected. RESULTS: Of 644 patients, appearance concerns were present in 72%, including 421 of 565 women (75%), 42 of 79 men (53%), 392 of 550 patients who identified as White (71%), 35 of 41 who identified as Black (85%), and 36 of 53 who identified as another race/ethnicity (68%). In multivariate analysis, women had significantly greater odds of reporting appearance concerns than men (odds ratio (OR)=2.97, 95% confidence interval (CI)=1.78-4.95, p<.001). Black patients had significantly greater odds of appearance concerns than White patients in unadjusted (OR=2.64, 95% CI=1.01-6.34, p=.030), but not multivariate analysis (OR=1.76, 95% CI=0.67-4.60, p=.250). Compared to a general population sample, appearance concerns were substantially more common in SSc, particularly for men across all age groups and for younger women. The most commonly reported features of concern were related to the face and head, followed by the hands and fingers; this did not differ by sex or race/ethnicity. CONCLUSIONS: Appearance concerns were common in SSc. Women were substantially more likely than men to have appearance concerns. Although non-significant in multivariate analysis, Black patients were more likely to have concerns than White patients, likely due to more severe changes in appearance

Pursuit of optimal outcomes in rheumatoid arthritis

The aim of this review is to describe methods of quantifying disease activity and symptomatology and discuss treatment goals for rheumatoid arthritis (RA). The benefits and limitations of existing therapeutic approaches, the importance of early therapy in preventing disease progression and the place of biologicals in early therapy will be discussed. Disease activity and symptomatology in RA are often measured using a set of core endpoints that incorporate pain, patient global assessment, physical disability, swollen joints, tender joints, acute phase reactants, physician global assessment and radiographic imaging of joints. Imaging of joints is the only means by which to measure the effects of disease-modifying antirheumatic drugs (DMARDs) on the irreversible joint damage that occurs during RA. There is increasing evidence that this damage and its functional consequences occur early in the onset of disease. The consensus is that patients with RA should be treated with DMARDs earlier rather than later in the disease process. Remission, or a state of sustained response or low disease activity that is not damaging or disabling, is the ideal goal of therapy for RA, but formal criteria defining a state of remission need to be revised and, ideally, updated to include a radiographic component. Currently available DMARDs are limited in their ability to achieve early, sustained response or remission, by delayed onset of action, cumulative toxicity and lack of long-term therapeutic response. It is hoped that the emergence of novel DMARDs - targeted biological agents, such as anti-tumour necrosis factor-alpha (anti-TNF-alpha) -will help to counteract such limitations and will allow early DMARD use to be adopted as standard practice in place of their use as a last resort therapy after failure of other treatment. One such biological agent, etanercept, has been shown to reduce radiographic disease progression and induce overall clinical response during the early stages of RA. It is significantly more effective and fast-acting than methotrexate, one of the most effective, commonly used DMARDs